The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone.

Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed ...

Sarclisa combination therapy reduced the risk of disease progression or death by 47% (hazard ratio 0.531, 99% CI 0.318-0.889, p=0.0007) versus standard of care Kd alone in patients with MM.

PARIS – June 2, 2020 – Sarclisa ® (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced the risk of disease progression or death by 47% (hazard ratio 0. ...

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies While the median progression free ...

PARIS – June 2, 2020 – Sarclisa ® (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced the risk of disease progression or death by 47% (hazard ratio 0. ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...